Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors-Reference-Cited by-同舟云学术

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

Published:2014-11 Issue:11 Volume:25 Page:2244-2251
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Soria J.-C.,DeBraud F.,Bahleda R.,Adamo B.,Andre F.,Dientsmann R.,Delmonte A.,Cereda R.,Isaacson J.,Litten J.,Allen A.,Dubois F.,Saba C.,Robert R.,D'Incalci M.,Zucchetti M.,Camboni M.G.,Tabernero J.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/11/2244/325838/mdu390.pdf

Reference27 articles.

1. Fibroblast growth factors and their receptors in cancer;Wesche;Biochem J,2011

2. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives;Dieci;Cancer Discov,2013

3. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis;Lieu;Clin Cancer Res,2011

4. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules;Grothey;Nat Rev Clin Oncol,2009

5. VEGF and the quest for tumour angiogenesis factors;Ferrara;Nat Rev Cancer,2002

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An insight into sustainable and green chemistry approaches for the synthesis of quinoline derivatives as anticancer agents;European Journal of Medicinal Chemistry;2024-09

2. Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer: mechanisms and role in endocrine resistance;Frontiers in Oncology;2024-07-08

3. Tumor biomarkers for diagnosis, prognosis and targeted therapy;Signal Transduction and Targeted Therapy;2024-05-20

4. Exploring FGFR signaling inhibition as a promising approach in breast cancer treatment;International Journal of Biological Macromolecules;2024-05

5. A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer;Journal of Advanced Research;2023-12